Skip to content

Study · Non-randomized trial · 2008

2 results

Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans.

Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Dec 2008Cited by 161 (Europe PMC)

PMID18684084 (opens in a new tab)PMCIDPMC2686921 (opens in a new tab)DOI10.1359/jbmr.080805 (opens in a new tab)PepBankPUB-18684084
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In osteoporotic postmenopausal women, simulated femoral strength increased 2.08% from baseline after PTH at year 1.

    In plain wordsIn osteoporotic women, simulated femoral strength increased from baseline after PTH at year 1.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    IncreaseFemoral strength change
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Strength change
    2.08%
    PTH at year 1

    Source sentences

    Summary
    At year 1, the strength change from baseline was statistically significant for PTH (mean, 2.08%) and ALN (3.60%),
    2 context sentences
    Summary · context
    The "PTH and Alendronate" or "PaTH" study compared the effects of PTH(1-84) and/or alendronate (ALN) in 238 postmenopausal, osteoporotic women.
    Summary · context
    We performed finite element analysis on the QCT scans of 162 of these subjects to provide insight into femoral strength changes associated with these treatments and the relative roles of changes in the cortical and trabecular compartments on such strength changes.
  2. 02HumanNon-randomized trialMechanism

    In osteoporotic postmenopausal women, external bone geometry changes after PTH at year 1 had significant negative strength effects.

    In plain wordsIn osteoporotic women, bone geometry changes after PTH at year 1 had negative effects on simulated strength.

    Peptide
    PTH 1-84 (parathyroid hormone)
    Outcome
    DecreaseGeometry-associated strength effect
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    For PTH treatment at year 1 and for ALN-ALN treatment at year 2, there were significant negative and positive strength effects, respectively, associated with a change in external bone geometry.
    2 context sentences
    Summary · context
    The "PTH and Alendronate" or "PaTH" study compared the effects of PTH(1-84) and/or alendronate (ALN) in 238 postmenopausal, osteoporotic women.
    Summary · context
    We performed finite element analysis on the QCT scans of 162 of these subjects to provide insight into femoral strength changes associated with these treatments and the relative roles of changes in the cortical and trabecular compartments on such strength changes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.